Ultrahuman has announced a partnership with Click Therapeutics to develop a migraine management feature for its smart ring platform. The Migraine PowerPlug, scheduled to launch in early 2026, will combine Ultrahuman’s biometric tracking with technology based on Click’s FDA-authorized digital therapeutic for migraine prevention.
The feature is positioned as a wellness tool rather than a medical device. According to the companies, it will help users track patterns across sleep, heart rate variability, stress, and activity levels that may correlate with migraine triggers. The tool will also provide guided behavioral interventions based on these insights.
Migraines affect women at nearly three times the rate of men, and the condition is the leading cause of disability among women aged 15 to 49. For many women, hormonal fluctuations are closely linked to migraine patterns—an area where Ultrahuman’s existing cycle tracking capabilities, bolstered by its recent acquisition of OvuSense, could provide additional context.
“By integrating the underlying principles of Click Therapeutics’ digital migraine treatment technology into our latest PowerPlug, we are enabling users to track and understand migraine-related patterns in real time, and then go further to turn those insights into actionable guidance,” said Mohit Kumar, CEO of Ultrahuman.
“Our partnership with Ultrahuman will allow us to bring a much-needed personalized migraine solution to people around the world,” said David Benshoof Klein, CEO and founder of Click Therapeutics.
The Migraine PowerPlug will launch in the United States, Canada, the EU, India, and Australia following a pilot phase.
